What is your approach to AYA patients with B-cell ALL who relapse after CD19 CAR-T?

This is a somewhat nuanced question based on when the patient relapsed after CAR-T, what CAR-T product they received, whether the patient prior received hematopoietic stem cell transplantation (HSCT), other salvage therapies that were prior received as well as number of prior relapses.

Multiple stra...

My approach differs based on whether or not the patient has had a prior allogeneic hematopoietic stem cell transplant (HSCT), and whether they relapse with CD19-positive (CD19+) or CD19-negative (CD19⁻) disease. For those patients who are transplant naive and have CD19+ relapse, the goal is to get t...